Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Regulatory authority and clinical acceptability : Physicians' responses to regulatory drug safety warnings. / Bhasale, Alice L.; Sarpatwari, Ameet; Lipworth, Wendy; Møllebæk, Mathias; McEwin, Eliza J.; Gautam, Nileesa; Santiago Ortiz, Adrian; Mintzes, Barbara J.
In: British Journal of Clinical Pharmacology, Vol. 88, No. 2, 2022, p. 713-722.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Regulatory authority and clinical acceptability
T2 - Physicians' responses to regulatory drug safety warnings
AU - Bhasale, Alice L.
AU - Sarpatwari, Ameet
AU - Lipworth, Wendy
AU - Møllebæk, Mathias
AU - McEwin, Eliza J.
AU - Gautam, Nileesa
AU - Santiago Ortiz, Adrian
AU - Mintzes, Barbara J.
PY - 2022
Y1 - 2022
N2 - Aims: Medicines regulators issue post-market safety warnings to advise of newly uncovered risks, but with mixed impacts. We aimed to identify factors influencing the use of regulatory warnings by primary care and specialist physicians in the US and Australia. Methods: Semi-structured qualitative interviews were carried out with 40 primary care physicians, endocrinologists and other generalist specialists in Boston (USA) and Australia. Coding and analysis were performed inductively and iteratively to identify and examine key factors. Analysis centred around four areas: physicians' awareness of drug safety information, preferred information sources, opinion-forming and sharing of information with patients. Results: Uncertainty, trust and clinical authority emerged as factors influencing use of advisories. Although regulators were trusted as authoritative institutions, they appeared to lack clinical authority, and physicians validated regulatory information against other trusted sources including evidence, expert opinion and experience. Specialists became aware of drug safety issues through specialised literature, using evidence and clinical consensus to form opinions. Primary care physicians, fielding high volumes of information, relied on convenient, accessible information sources including the media and the ?clinical grapevine? for awareness, and on clinical colleagues, specialists and experience for interpretation. Communicating risk to patients was complicated by uncertainty; physicians tailored information to patients' health literacy and information needs. US physicians were more aware of their national regulator's post-market safety role than Australian physicians of theirs. Conclusion: Drug safety warnings may not be optimally received or used. Regulators should consider strategies that increase trust, clinical relevance and accessibility, and address physicians' needs in communicating risk to patients.
AB - Aims: Medicines regulators issue post-market safety warnings to advise of newly uncovered risks, but with mixed impacts. We aimed to identify factors influencing the use of regulatory warnings by primary care and specialist physicians in the US and Australia. Methods: Semi-structured qualitative interviews were carried out with 40 primary care physicians, endocrinologists and other generalist specialists in Boston (USA) and Australia. Coding and analysis were performed inductively and iteratively to identify and examine key factors. Analysis centred around four areas: physicians' awareness of drug safety information, preferred information sources, opinion-forming and sharing of information with patients. Results: Uncertainty, trust and clinical authority emerged as factors influencing use of advisories. Although regulators were trusted as authoritative institutions, they appeared to lack clinical authority, and physicians validated regulatory information against other trusted sources including evidence, expert opinion and experience. Specialists became aware of drug safety issues through specialised literature, using evidence and clinical consensus to form opinions. Primary care physicians, fielding high volumes of information, relied on convenient, accessible information sources including the media and the ?clinical grapevine? for awareness, and on clinical colleagues, specialists and experience for interpretation. Communicating risk to patients was complicated by uncertainty; physicians tailored information to patients' health literacy and information needs. US physicians were more aware of their national regulator's post-market safety role than Australian physicians of theirs. Conclusion: Drug safety warnings may not be optimally received or used. Regulators should consider strategies that increase trust, clinical relevance and accessibility, and address physicians' needs in communicating risk to patients.
KW - drug safety
KW - pharmacovigilance
KW - prescriber attitudes
KW - qualitative methods
KW - risk communication
U2 - 10.1111/bcp.15007
DO - 10.1111/bcp.15007
M3 - Journal article
C2 - 34337777
VL - 88
SP - 713
EP - 722
JO - British Journal of Clinical Pharmacology, Supplement
JF - British Journal of Clinical Pharmacology, Supplement
SN - 0264-3774
IS - 2
ER -
ID: 276268929